8-K
NEWCabaletta Bio Presents Positive Phase 1/2 Clinical Data for Rese-cel Across Multiple Autoimmune Diseases at ACR Convergence 2026
8-K
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
8-K
Cabaletta Bio Announces Results of Common Stock Warrant Exercises Totaling $128.2 Million in Gross Proceeds
8-K
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Business Update
8-K
Cabaletta Bio, Inc. Announces Results of 2026 Annual Meeting and Approval of Authorized Share Increase
8-K
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio
